Biyang Bio
比洋生物
Biyang Bio
Biotech/Healthcare
Beijing Biyang Biotechnology Co., Ltd. focuses its R&D on bispecific antibodies and long-acting immune fusion proteins, covering three major therapeutic areas: oncology, diabetes, and autoimmune diseases.
Latest round: Series A (2022)
Source: ChinaBulls — chinabulls.com
Last updated 2022-07-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.